What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence suggests that latanoprost-netarsudil is as effective as bimatoprost-timolol, demonstrating non-inferiority. However, indirect comparisons with other fixed-dose combination treatments are highly uncertain, indicating comparable efficacy but lacking definitive superiority.
Does the economic case hold at the expected price? — Cost effectiveness
Latanoprost-netarsudil is associated with similar or lower costs compared to most branded and some generic fixed-dose combination treatments. The cost-comparison analysis indicates it is likely to be cost-effective, aligning with common thresholds.
Is there quality-of-life evidence payers weigh? — Quality of life
The document discusses the significant impact of glaucoma and ocular hypertension on quality of life, highlighting the burden of multiple treatments. The introduction of latanoprost-netarsudil as a once-daily treatment option is expected to alleviate some of these burdens, thus providing moderate improvements in HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of latanoprost-netarsudil is acceptable, with mild adverse effects such as eye redness reported. These effects are generally manageable and reversible, indicating a good tolerability compared to existing treatments.
Was the drug compared against what payers expect? — Comparator Selection
The evaluation committee concluded that all fixed-dose combination eye drops should be considered relevant comparators for latanoprost-netarsudil, indicating a strong selection of comparators that reflect current clinical practice.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population adequately reflects the licensed population for latanoprost-netarsudil, and the document indicates that the patient population is representative of those with primary open-angle glaucoma or ocular hypertension.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Latanoprost-netarsudil is expected to integrate well into existing treatment pathways, requiring only minor adjustments. It is positioned as a treatment option after other therapies have failed, which aligns with current clinical practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model indicates that latanoprost-netarsudil has a manageable budget impact and is likely to be resource-efficient compared to existing treatments, supporting its adoption in clinical practice.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes a phase 3 RCT (MERCURY 3) demonstrating non-inferiority to a comparator, although there are some concerns regarding the indirect comparisons made. Overall, the evidence is robust but has some limitations.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties related to the indirect comparisons and the economic model, the overall context of unmet need and the potential benefits of a new treatment option mitigate some of these concerns.
